Utility of diffusion weighted imaging (DWI) in assessment of liver fibrosis by Emara, Doaa M. et al.
Alexandria Journal of Medicine 54 (2018) 347–352Contents lists available at ScienceDirect
Alexandria Journal of Medicine
journal homepage: ht tp : / /www.elsevier .com/locate /a jmeOriginal ArticleUtility of diffusion weighted imaging (DWI) in assessment of liver
fibrosishttps://doi.org/10.1016/j.ajme.2017.06.007
2090-5068/ 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of Alexandria University Faculty of Medicine.
⇑ Corresponding author.
E-mail address: dr.emara_doaa@yahoo.com (D.M. Emara).Doaa M. Emara a,⇑, Marwa M. Reda b, Doaa A. Elwazzan c
aDepartment of Radiology, Faculty of Medicine, Alexandria University, Egypt
bHepatobiliary Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt
cDepartment of Tropical Medicine, Faculty of Medicine, Alexandria University, Egypt
a r t i c l e i n f o a b s t r a c tArticle history:
Received 29 October 2016
Revised 21 April 2017
Accepted 19 June 2017
Available online 9 October 2017Objectives: hepatic fibrosis occurs due to chronic liver injury. Early fibrosis can be reversed by treatment
with specific antifibrotic therapy in addition to removal of the cause if possible, that is why, identification
of the early liver fibrosis is important. MRI DWI is a non-invasive non-contrast imaging technique which
help in diagnosis of different stages of hepatic fibrosis. Aim of the work: was to study the predictive value
of diffusion weighted MRI for assessing liver fibrosis in comparison to liver biopsy in chronic hepatitis C
virus patients. Methods: all the studied cases were subjected to the followings: (1) History and laboratory
examination (PCR for HCV and liver function tests). (2) MRI DWI and post processing ADC map. (3)
Percutaneous liver biopsy in cases with HCV for histopathological examination to assess the stage of
fibrosis. Results: this study was carried out on 75 subjects, divided into two group, 50 cases and 25 con-
trols, the mean age in the two studied groups was 36.5 ± 9.32 and 35.8 ± 6.75 respectively in patients and
control. ADC of both liver and spleen showed a highly significant increase in the control than in the cases
with mean liver ADC in the control group = 2.3 ± 0.25. There was a significant negative correlation
between the mean ADC of the liver, spleen and the stage of liver fibrosis.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatic fibrosis occurs due to chronic liver injury that usually
leads to collapse of hepatic lobules, formation of fibrous septae
and hepatocyte regeneration with nodule formation.1 Extracellular
matrix components accumulate in the liver as a result of imbal-
ances in their production, deposition and degradation.2 At the
end, this process will progress to cirrhosis, portal hypertension,
hepatocellular failure and hepatocellular carcinoma in some
patients.3
There are multiple causes for chronic liver injury,4,5 in Egypt,
hepatitis C virus (HCV) genotype 4 infection is the most common
cause. Egypt has the highest prevalence of HCV in the world, esti-
mated nationally at 14.7%.6,7
Early fibrosis can be reversed by treatment with specific antifi-
brotic therapy in addition to removal of the cause if possible, that is
why, identification of the early liver fibrosis is important.2,8,9
Liver biopsy (LB) is the gold standard and the reference method
for determining histological grading (the extent of necroinflamma-tory activity) and staging (the extent of fibrosis) to assess the cur-
rent status of the liver, to provide prognostic information for future
disease progression and treatment decisions as it may reveal
advanced fibrosis or cirrhosis that necessitates surveillance for
HCC and screening for esophageal varices.10,11 However, liver
biopsy is invasive, painful and limited by intra-and inter-
observer variation and sampling errors, moreover, it can be com-
plicated by hemorrhage, pneumothorax, peritonitis, penetration
of abdominal organs and death.12–14 Therefore, reliable and nonin-
vasive methods for assessment and quantification of hepatic fibro-
sis are needed. There are different noninvasive methods that have
been developed for assessment of fibrosis as an alternative to the
LB.15 These methods are based on clinical, biochemical, and radio-
logic variables that can be used in combination.16 If noninvasive
methods provide a clear-cut assessment of hepatic fibrosis then
further assessment with liver biopsy may not be needed, but ques-
tions remain regarding the cut-off values for the degree of fibrosis,
cost, and validity of these tests, which should be answered through
performing multiple studies.16,17
Noninvasive serum markers can be good clinical alternatives in
patients who are not candidates for liver biopsy, they can predict
presence or absence of significant fibrosis/cirrhosis, but are not
useful in differentiating between intermediate stages of fibrosis.
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these markers.17–19
Radiologic imaging has been used to estimate fibrosis. Ultra-
sound transient elastography is an example, which shows promis-
ing results in identifying stages of liver fibrosis, but its results are
influenced by multiple factors such as obesity, hepatic inflamma-
tion and ascites. Thus, it is better to combine transient elastogra-
phy results with other measures of hepatic fibrosis.20,21
Both CT and conventional MRI did not show high sensitivity for
early stages of fibrosis, However, diffusion-weighted magnetic res-
onance imaging (DW-MRI) has been shown better results in diag-
nosing early fibrosis.22
DWI-MRI is a technique in which water diffusion is quantified
by the calculation of the apparent diffusion coefficient (ADC)
because DWI-MRI is sensitive to the microscopic movement of
water molecules.22,23
DWI-MRI has many advantages, it is rapid, non-invasive and
non-contrast imaging technique, but MR diffusion quantifications
can be affected by some factors such as permeability, perfusion
and cellular structure. In patients with chronic liver disease, ADC
values are lower which may be explained by the deposition of pro-
teoglycan and glycosaminoglycan fibers in the liver with subse-
quent restriction of the diffusion of water molecules.23–252. Aim of the work
Was to study the predictive value of diffusion weighted MRI for
assessing liver fibrosis in comparison to liver biopsy in chronic
hepatitis C virus patients.
2.1. Subjects and methods
This study was conducted on 75 subjects, divided into two
groups, 50 cases with chronic viral hepatitis C and 25 age and
sex matched healthy subjects with no evidence of liver disease.
These cases were referred from hepatobiliary and tropical medi-
cine units to radiology department for DWI-MRI in the duration
between June 2013 till June 2014.
The exclusion criteria were: hepatitis B virus (HBV) infection,
alcohol consumption, obesity, concomitant schistosomiasis, bleed-
ing diathesis, hepatic decompensation, chronic diseases such as
diabetes mellitus or connective tissue diseases, malignancies,
previous anti-viral or systemic anti-cancer therapy. Also absolute
contraindication to MRI or refusing MRI imaging were considered.
The study protocol was approved by the Research Review Com-
mittee of the Alexandria Faculty of Medicine and was conformed to
the 1975 Declaration of Helsinki. An informed consent was
obtained from each subject included in the study.
All the studied cases were subjected to the followings:
(1) History and laboratory examination (PCR for HCV and
liver function tests).
(2) MRI DWI and post processing ADC map.
(3) Percutaneous liver biopsy in cases with HCV for histopatho-
logical examination to assess the stage of fibrosis.
2.2. MRI examination
It was done for all patients one day before or at the same day of
liver biopsy procedure but before it to avoid false results from
bleeding that affects the DWI/ADC. The examination was done on
1.5T superconducting magnet MRI machines Philips Gyroscan
Intera version 12.1.1.2 (Best, The Netherlands). The patient was
placed in supine position; arms extended above head. A phased
array surface coil was used.DWI with b value 500 s/mm2 with TR 1000, TE 137, flip angle
90, FOV 370, slice thickness 7 mm and automatically computer-
generated ADC map.
DWI was interpreted in correlation with ADC map and ADC
value was calculated in 103 mm2/s using dedicated workstation.
Four ROIs for ADC values were measured for each case, two ROIs
away from the blood vessels in each lobe of the liver with each
ROI = 1–1.5 cm2. The final ADC value was the average of the four
ROIs.
Normalized ADC was calculated as ratio between the mean ADC
of the liver and that of the spleen Fig. 1.
2.3. Liver biopsy
All patients were subjected to pretreatment liver biopsy as rou-
tine prerequisites for antiviral therapy to evaluate the degree of
activity for chronic hepatitis (grading), and the presence or absence
of fibrosis (staging) according to METAVIR scoring system.26,27 The
histopathological findings were correlated with DW-MRI.
2.4. Procedure of the liver biopsy28,29
It was done as an inpatient procedure (only for 6 h of admis-
sion) in the ultrasound room in Hepatobiliary Unit, Department
of internal medicine and Department of tropical medicine at
Alexandria Main University Hospital.
1. Examination of blood coagulation profile (platelet count, pro-
thrombin activity).
2. Informed consent was obtained in writing on the same day of
the planned biopsy.
3. Ultrasound-guided transcutaneous liver biopsy was done via
an intercostal route using automatic Tru-Cut needle (‘‘biopsy
gun”) 16 gauge in diameter and 20 cm length with the patient
positioned left lateral with the right arm elevated behind the
head.
2.5. Sample size
Sample size was calculated based on a previous study by using
Med Calc statistical software. Assuming area under ROC to be 0.80,
an alpha of 0.05 and power of study 80.0%. A minimum sample size
required was 50 patients and 25 control will be required for this
study.
2.6. Statistical analysis
The Data was collected and entered into the personal computer.
Statistical analysis was done using Statistical Package for Social
Sciences (SPSS/version 20) software.
Arithmetic mean, standard deviation, for categorized parame-
ters, chai square test was used, while for numerical data, t-test
was used to compare two groups while for more than two groups
ANOVA test was used. To find the association between two vari-
ables, Spearman correlation coefficient test was used and the level
of significance was 0.05.
3. Results
This study was carried out on 75 subjects, divided into two
group, 50 cases and 25 control, the mean age in the two studied
groups was 36.5 ± 9.32 and 35.8 ± 6.75 respectively in patients
and control, there was no significant difference between the two
groups regarding age (p > 0.05), the male to female ratio in the
two groups was matched, the BMI in patients was 24.59 ± 2.58
Fig. 1. ADC map demonstrates measurements of ADC value of the liver and that of the spleen.
Table 1
Characteristic features of the studied groups.
Group p
Patients Control
Age 36.50 ± 9.32 35.80 ± 6.75 0.739
Sex 19 38.0% 13 52.0% 0.248
Female 31 62.0% 12 48.0%
Male
BMI 24.59 ± 2.58 23.55 ± 2.57 0.102
D.M. Emara et al. / Alexandria Journal of Medicine 54 (2018) 347–352 349and in control was 23.55 ± 2.57, on comparing the two groups it
was found that there was no significant difference regarding BMI
(Table 1).Regarding the laboratory findings, it was found that there was a
slightly significant increase in RBCs in patients more than the con-
trol, the Platelet count in patients was significantly lower than in
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nificant difference between patients and control. Fasting blood glu-
cose in the two groups was within normal without significant
difference while there was a slightly increase in 2 h post prandial
blood sugar in patients than in the control. Blood urea showed a
significant increase in patients than in the control, while the crea-
tinine showed insignificant difference between patients and con-
trol. Serum cholesterol and triglyceride showed a significant
difference between patients and control. TSH, Free T3 showed a
significant increase in patients than the control, but free T4 was
matched in the two groups. Liver enzymes showed a significant
increase in patients than the control. Serum bilirubin, Prothrombin
activity (PA) and alfa fetoprotein (AFP) showed no significant dif-
ference in the two groups (Table 2).Table 2
Comparison between the two studied groups regarding the laboratory and DWI
findings.
Patient Control P
HB 13.95 ± 1.23 14.06 ± 0.91 0.694
RBCs 5.14 ± 0.84 4.76 ± 0.66 0.05*
Platelet count (103/cmm) 231.88 ± 87.47 316.60 ± 71.62 0.0001*
WBCs 5.98 ± 1.90 5.41 ± 0.71 0.150
FBS 81.04 ± 7.34 81.36 ± 9.59 0.873
2 h PPS 107.12 ± 11.68 101.96 ± 8.48 0.05*
Blood urea 24.18 ± 9.27 20.12 ± 6.56 0.05*
Serum creatinine (mg/dl) 0.71 ± 0.20 0.78 ± 0.19 0.166
Serum cholesterol 133.32 ± 22.62 155.56 ± 31.25 0.001*
Serum triglyceride 107.20 ± 19.80 125.56 ± 22.66 0.001*
TSH 2.51 ± 0.65 2.12 ± 0.56 0.013*
Free T3 3.44 ± 0.31 3.30 ± 0.27 0.045*
Free T4 1.27 ± 0.28 1.19 ± 0.24 0.235
Serum AST 46.00 ± 25.30 20.32 ± 3.86 0.0001*
Serum ALT 52.82 ± 27.06 20.80 ± 4.09 0.0001*
Serum alkaline phosphatase 49.04 ± 16.41 41.56 ± 14.09 0.05*
Serum GGT 18.84 ± 5.89 21.04 ± 3.23 0.087
Serum albumin (g/dl) 4.40 ± 0.48 4.65 ± 0.43 0.032*
Serum bilirubin (mg/dl) 0.71 ± 0.15 0.64 ± 0.16 0.074
PA 92.29 ± 7.78 93.16 ± 4.81 0.609
AFP 4.22 ± 2.53 4.87 ± 1.53 0.242
Mean ADC (liver) 1.42 ± 0.19 1.70 ± 0.03 0.0001*
ADC spleen 1.03 ± 0.20 1.32 ± 0.03 0.0001*
Table 3








Relation between mean ADC (liver) and ADC (spleen) and stage of liver fibrosis.
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4 3 0.8860The study included 9 patients with F0, 16 patients with F1, 7
patients with F2, 15 patients with F3 and 3 patients with F4
Table 3.
ADC of both liver and spleen showed a highly significant
increase in the control than in the cases with mean liver ADC in
the control group = 2.3 ± 0.25.
The relation between the stage of liver fibrosis and mean ADC of
the liver and spleen was shown in Table 4; there was a significant
negative correlation between the mean ADC of the liver, spleen and
the stage of liver fibrosis.
The ROC curve was done to calculate the cut off value of ADC of
the liver and the mean normalized ADC to detect the stage of liver
fibrosis. In the detection of stage 3 as a base line, mean ADC of the
liver and cut off value was 1.15, the area under the curve was 0.89
with sensitivity of 86% and 85%, and specificity was 90% and 90%
respectively. Regarding mean normalized ADC the area under the
curve was 0.52 and the cut off value was 0.52 to detect the stage
less or more than 2, the sensitivity was 61% and 60% and the speci-
ficity was 60.3% and 55% (Fig. 2, Table 5).
The pearson correlation coefficient between different studied
makers showed that there was a positive significant correlation
between AFP and mean ADC of the liver, and there was a significant
positive correlation between mean ADC of the liver and spleen
(Table 6).4. Discussion
Liver biopsy gives a snapshot and not an insight into the natural
history of liver fibrosis and the dynamic changes during the pro-
cess of fibrogenesis whether progression, static or regression as it
needs repeated biopsies through the course of the disease which
is not applicable in clinical field. At the same time, liver biopsy is
an invasive procedure, carrying a risk of rare but potentially life-
threatening complications 10,12; however after recent development
in MRI, there are different techniques that can be used to assess the
fibrosis with more or less high accuracy, and one of these tech-
niques is DWI/ADC which is non- invasive reliable method.22
The decrease in ADC value among patients with liver fibrosis is
attributed to accumulation of glycosaminoglycane, proteoglycane
and collagen fibers within the liver and consequently restricted dif-
fusion of water molecules.30
Kumaresan et al., Richard et al., Hasan et al.23,31,32 concluded
that the ADC value in fibrotic liver is significantly lower than that
of normal liver, in our cases, we confirmed that as we detected high
ADC value of the liver among control group.
In our study we found that there is significant negative correla-
tion between the stage of liver fibrosis and ADC value of the liver,
this was also confirmed in different studies.30,32,33
The cut off value, in the current study, of the liver ADC in stage 3
or less is 1.15 with sensitivity and specificity of 86% & 90% respec-











Fig. 2. ROC curve and the cut off value of both mean ADC liver and normalized ADC in detecting the stage of liver fibrosis.
Table 5
The cut off value of both mean ADC liver and normalized ADC in detecting the stage of fibrosis.
Stage Area under the curve (AUC) Cut off value Sensitivity Specificity
Mean ADC (Liver)
Stage  3 0.89 >1.15 0.86 0.90
Stage > 3 <1.15 0.85 0.90
Mean normalized ADC
Stage  3 0.52 >0.52 0.610 0.607
Stage > 3 <0.52 0.60 0.55
Table 6
Correlation between different parameters of the studied patients.
PA AFP Mean ADC (liver)
AFP Pearson correlation 0.122
p 0.297
Mean ADC (liver) Pearson correlation 0.068 0.253*
p 0.559 0.029
ADC spleen Pearson correlation 0.090 0.071 0.774**
p 0.440 0.542 0.0001*
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high b values is 1.3 with 89% sensitivity and 88% specificity.22,23
In other study, they found variable measurements of liver ADC
with mean ADC in mild fibrosis = 0.97 while in advanced
fibrosis = 0.78.32
The variation in ADC values among fibrotic liver in different
studies may be attributed to different machines that have been
used together with variation in b values used in DWI/ADC.We used the normalized ADC value which is the ADC of the
liver/that of the spleen as another measurement method to con-
firm the relation between DWI/ADC and stage of liver fibrosis
and this was in agreement with Mona El-Hariri, et al.25
In the current study there was a significant relation between
the normalized ADC of the liver and the stage of liver fibrosis with
AUC = 0.52 and cut off value for stage 3 was 0.52 with a sensitivity
and specificity = 61% & 60% respectively. Richard et al.31 also
352 D.M. Emara et al. / Alexandria Journal of Medicine 54 (2018) 347–352confirmed this in their study as they found the normalized liver
ADC distinguished between individual groups of fibrosis with sig-
nificant differences between control subjects and intermediate
stages of fibrosis (stages 2 and 3).
Although DWI-MRI proved to be useful in differentiating differ-
ent stages of liver fibrosis, in our study, we found overlap between
stages F0, F1 and F2 which is in agreement with Kumaresan et al.23
and Hasan et al.32 confirmed that in their study, and so DWI/ADC of
the liver can divide the patients into two main groups <F3 and >F3,
yet this overlap does not affect the treatment regimen.
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